Immutep receives French R&D rebate, lifting recent tax incentive funding to about $3 million
IMM: $0.024 +9.09% · MC: $35M
Immutep received approximately A$2 million from France’s R&D tax incentive for eligible research conducted in 2025, following an Australian R&D rebate of about A$1 million announced last month. The company says the non-dilutive funding will support research on eftilagimod alfa and IMP761, and its expected cash reach extends into the first half of 2028.

Comments